Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A global network of scientific, medical and research trial collaborators works together on COPCOV, the MORU-led, Oxford-supported study to test if hydroxychloroquine or chloroquine can prevent COVID-19. 

As vaccines begin to roll out, finding drugs that prevent COVID-19 is more important than ever: It may be mid-2022 before there are enough COVID-19 vaccines for the 7.5 billion people on this planet. Scientifically proving that hydroxychloroquine provides even a small health benefit could save thousands of lives before vaccines become widely available, and COVID-19 brought under control. Understanding whether these drugs can effectively prevent COVID-19 infection would also support global preparedness for future potential emerging viral threats.

Currently, there are active COPCOV sites in Kenya, Zambia and Pakistan, with new sites opening soon in other African countries. In addition, sites in Thailand and Lao PDR are set up, ready to be re-activated should COVID-19 re-emerge there.

Principal Investigators


Trial Researchers